TMO - Thermo Fisher Scientific Inc.
NYSE
->
Healthcare
->
Diagnostics & Research
Waltham,
United States
Type: Equity
TMO price evolution
TMO
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8077 | $6151 | $3133 | $3482 |
| Short term investments | ||||
| Net receivables | $8221 | $8370 | $8019 | $7922 |
| Inventory | $5088 | $5404 | $5655 | $5664 |
| Total current assets | $24589 | $23092 | $19995 | $20209 |
| Long term investments | ||||
| Property, plant & equipment | $9448 | $9167 | $9292 | $9354 |
| Goodwill & intangible assets | $60690 | $60674 | $60710 | $61112 |
| Total noncurrent assets | $74137 | $73965 | $74110 | $74449 |
| Total investments | ||||
| Total assets | $98726 | $97057 | $94105 | $94658 |
| Current liabilities | ||||
| Accounts payable | $2872 | $2508 | $2423 | $2798 |
| Deferred revenue | $2689 | $2547 | $2590 | $2662 |
| Short long term debt | $3609 | $4795 | $4814 | $6122 |
| Total current liabilities | $14012 | $14158 | $14112 | $15884 |
| Long term debt | $31308 | $30489 | $29194 | $29135 |
| Total noncurrent liabilities | $37990 | $37553 | $36191 | $36464 |
| Total debt | $34917 | $35284 | $34008 | $35257 |
| Total liabilities | $52002 | $51711 | $50303 | $52348 |
| Shareholders' equity | ||||
| Retained earnings | $47364 | $45869 | $44289 | $43064 |
| Other shareholder equity | $46724 | $45346 | -$2924 | -$3054 |
| Total shareholder equity | $46735 | $45328 | $43752 | $42257 |
| (in millions $) | 31 Jan 2024 | 31 Jan 2023 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Current assets | ||||
| Cash | $8077 | $8524 | $4477 | $10325 |
| Short term investments | ||||
| Net receivables | $8221 | $8274 | $7977 | $5741 |
| Inventory | $5088 | $5634 | $5051 | $4029 |
| Total current assets | $24589 | $25365 | $20113 | $21957 |
| Long term investments | $53 | |||
| Property, plant & equipment | $9448 | $9280 | $8333 | $5912 |
| Goodwill & intangible assets | $60690 | $58638 | $62037 | $38726 |
| Total noncurrent assets | $74137 | $71925 | $75010 | $47095 |
| Total investments | ||||
| Total assets | $98726 | $97290 | $95123 | $69052 |
| Current liabilities | ||||
| Accounts payable | $2872 | $3381 | $2867 | $2175 |
| Deferred revenue | $2689 | $2601 | $2655 | $1271 |
| Short long term debt | $3609 | $5579 | $2537 | $2628 |
| Total current liabilities | $14012 | $17114 | $13436 | $10304 |
| Long term debt | $31308 | $28909 | $32333 | $19107 |
| Total noncurrent liabilities | $37990 | $36112 | $40832 | $24241 |
| Total debt | $34917 | $34488 | $34870 | $21735 |
| Total liabilities | $52002 | $53258 | $54268 | $34545 |
| Shareholders' equity | ||||
| Retained earnings | $47364 | $41910 | $35431 | $28116 |
| Other shareholder equity | $46724 | $44032 | -$2329 | -$2807 |
| Total shareholder equity | $46735 | $43978 | $40793 | $34507 |
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jul 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $10886 | $10574 | $10710 | |
| Cost of revenue | $6570 | |||
| Gross Profit | $4496 | $4429 | $4140 | |
| Operating activities | ||||
| Research & development | $346 | |||
| Selling, general & administrative | $2119 | |||
| Total operating expenses | $2562 | $2481 | $2577 | |
| Operating income | $1563 | |||
| Income from continuing operations | ||||
| EBIT | $1635 | |||
| Income tax expense | $133 | $53 | $46 | |
| Interest expense | -$81 | -$113 | $300 | |
| Net income | ||||
| Net income | $1630 | $1715 | $1289 | |
| Income (for common shares) | $1289 | |||
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Jan 2022 | 31 Dec 2020 |
|---|---|---|---|---|
| Revenue | ||||
| Total revenue | $42857 | $44915 | $32218 | |
| Cost of revenue | $25944 | $16214 | ||
| Gross Profit | $17562 | $18971 | $16004 | |
| Operating activities | ||||
| Research & development | $1471 | $1181 | ||
| Selling, general & administrative | $8993 | $6930 | ||
| Total operating expenses | $10244 | $10578 | $8210 | |
| Operating income | $8393 | $7794 | ||
| Income from continuing operations | ||||
| EBIT | $8379 | $7778 | ||
| Income tax expense | $284 | $703 | $850 | |
| Interest expense | -$496 | $726 | $553 | |
| Net income | ||||
| Net income | $5995 | $6950 | $6375 | |
| Income (for common shares) | $6950 | $6375 | ||
| (in millions $) | 31 Jan 2024 | 30 Oct 2023 | 30 Jun 2023 | 31 Mar 2023 |
|---|---|---|---|---|
| Net income | $1361 | $1289 | ||
| Operating activities | ||||
| Depreciation | $855 | $859 | ||
| Business acquisitions & disposals | -$47 | -$2704 | ||
| Stock-based compensation | $74 | $76 | ||
| Total cash flows from operations | $1540 | $729 | ||
| Investing activities | ||||
| Capital expenditures | -$280 | -$452 | ||
| Investments | ||||
| Total cash flows from investing | -$5142 | -$4766 | -$443 | -$3142 |
| Financing activities | ||||
| Dividends paid | -$523 | -$387 | -$135 | -$117 |
| Sale and purchase of stock | -$3000 | |||
| Net borrowings | -$1325 | $504 | ||
| Total cash flows from financing | -$3622 | -$2194 | -$1456 | -$2593 |
| Effect of exchange rate | -$82 | -$92 | $12 | -$31 |
| Change in cash and equivalents | -$440 | -$2369 | -$347 | -$5037 |
| (in millions $) | 31 Jan 2024 | 31 Dec 2022 | 31 Dec 2021 | 31 Dec 2020 |
|---|---|---|---|---|
| Net income | $6950 | $7725 | $6375 | |
| Operating activities | ||||
| Depreciation | $3381 | $2592 | $2325 | |
| Business acquisitions & disposals | -$39 | -$19395 | -$38 | |
| Stock-based compensation | $307 | $230 | $196 | |
| Total cash flows from operations | $9154 | $9312 | $8289 | |
| Investing activities | ||||
| Capital expenditures | -$2219 | -$2503 | -$1466 | |
| Investments | ||||
| Total cash flows from investing | -$5142 | -$2159 | -$21932 | -$1510 |
| Financing activities | ||||
| Dividends paid | -$523 | -$455 | -$395 | -$337 |
| Sale and purchase of stock | -$3000 | -$1844 | -$1304 | |
| Net borrowings | $654 | $8911 | $2747 | |
| Total cash flows from financing | -$3622 | -$2810 | $6581 | $959 |
| Effect of exchange rate | -$82 | -$139 | $194 | $176 |
| Change in cash and equivalents | -$440 | $4046 | -$5845 | $7914 |
News
Fundamentals
| Market cap | $222.01B |
|---|---|
| Enterprise value | $248.85B |
| Shares outstanding | 386.37M |
| Revenue | N/A |
|---|---|
| EBITDA | N/A |
| EBIT | N/A |
| Net Income | N/A |
| Revenue Q/Q | -4.93% |
| Revenue Y/Y | N/A |
| P/E ratio | N/A |
|---|---|
| EV/Sales | N/A |
| EV/EBITDA | N/A |
| EV/EBIT | N/A |
| P/S ratio | N/A |
| P/B ratio | 20.18K |
| Book/Share | 0.03 |
| Cash/Share | 20.90 |
| EPS | N/A |
|---|---|
| ROA | N/A |
| ROE | N/A |
| Debt/Equity | 1.11 |
|---|---|
| Net debt/EBITDA | N/A |
| Current ratio | 1.75 |
| Quick ratio | 1.39 |